Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.47 |
| ▸ | ANPEP | P15144 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 2/20 | 0.36 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7447674 | 1.00 | MMP2 (0.47) | MMP2ANPEPALDH1A1PEPDXPNPEP1 | |
| SCHEMBL31556015 | 1.00 | MMP2 (0.47) | MMP2ANPEPALDH1A1PEPDXPNPEP1 | |
| SCHEMBL13745872 | 0.86 | MMP2 (0.49) | MMP2ANPEPALDH1A1PEPDXPNPEP1 | |
| SCHEMBL3405107 | 0.86 | MMP2 (0.49) | MMP2ANPEPALDH1A1PEPDXPNPEP1 | |
| SCHEMBL7342368 | 0.86 | MMP2 (0.65) | MMP2ANPEPALDH1A1PEPDXPNPEP1 | |
| SCHEMBL7342364 | 0.86 | MMP2 (0.65) | MMP2ANPEPALDH1A1PEPDXPNPEP1 | |
| SCHEMBL5160994 | 0.85 | ATM (0.43) | MMP2ANPEP | |
| SCHEMBL3440720 | 0.85 | ATM (0.43) | MMP2ANPEP | |
| SCHEMBL19064872 | 0.85 | ATM (0.43) | MMP2ANPEP | |
| SCHEMBL6596413 | 0.85 | ATM (0.43) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2175933-B1 | TRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| EP-2175933-A1 | TRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009015254-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-0918768-B1 | AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS | C & C RES LAB (KR) | 2002-01-09 | — | — | EP | disclosed |
| US-6201006-B1 | ANTICOAGULANTS | C & C RESEARCH LABORATORIES (KR) | 2001-03-13 | — | — | US | disclosed |
| EP-0918768-A1 | AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS | C & C Research Laboratories (KR) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997045424-A1 | AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS | C & C RESEARCH LABORATORIES (KR) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | ABL1, STK25, FLT3 | MMP2 2508/4885ANPEP 1962/4885ALDH1A1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.